Suppr超能文献

心室管理起搏与VVI 40起搏(MVP)试验:临床背景、原理、设计与实施

The Managed Ventricular pacing versus VVI 40 Pacing (MVP) Trial: clinical background, rationale, design, and implementation.

作者信息

Sweeney Michael O, Ellenbogen Kenneth A, Miller Elaine Hogan, Sherfesee Lou, Sheldon Todd, Whellan David

机构信息

Brigham and Women's Hospital, Boston, Massachusetts 02115, USA.

出版信息

J Cardiovasc Electrophysiol. 2006 Dec;17(12):1295-8. doi: 10.1111/j.1540-8167.2006.00656.x. Epub 2006 Nov 1.

Abstract

BACKGROUND

Implantable cardioverter defibrillators (ICDs) reduce mortality among appropriately selected patients who have had or are at risk for life-threatening ventricular arrhythmia. Right ventricular apical (RVA) pacing has been implicated in worsening heart failure and death. The optimal pacemaker mode for bradycardia support while minimizing unnecessary and potentially harmful RVA pacing has not been determined.

METHODS

The Managed Ventricular pacing vs. VVI 40 Pacing Trial (MVP) is a prospective, multicenter, randomized, single-blind, parallel, controlled clinical trial designed to establish whether atrial-based dual-chamber managed ventricular pacing mode (MVP) is equivalent or superior to back-up only ventricular pacing (VVI 40) among patients with standard indications for ICD therapy and no indication for bradycardia pacing. The MVP Trial is designed with 80% power to detect a 10% reduction in the primary endpoint of new or worsening heart failure or all-cause mortality in the MVP-treated group. Approximately 1,000 patients at 80 centers in the United States, Canada, Western Europe, and Israel will be randomized to MVP or VVI 40 pacing after successful implantation of a dual-chamber ICD. Heart failure therapies will be optimized in accordance with evidence-based guidelines. Prespecified secondary endpoints will include ventricular arrhythmias, atrial fibrillation, new indication for bradycardia pacing, health-related quality of life, and cost effectiveness. Enrollment began in October 2004 and concluded in April 2006. The study will be terminated upon recommendation of the Data Monitoring Committee or when the last patient enrolled and surviving has reached a minimum 2 years of follow-up.

CONCLUSION

The MVP Trial will meet the clinical need for carefully designed prospective studies to define the benefits of atrial-based dual-chamber minimal ventricular pacing versus single-chamber ventricular pacing in conventional ICD patients.

摘要

背景

植入式心脏复律除颤器(ICD)可降低经适当选择的、曾发生或有危及生命的室性心律失常风险的患者的死亡率。右心室心尖部(RVA)起搏与心力衰竭恶化和死亡有关。在将不必要且可能有害的RVA起搏降至最低的同时,用于缓慢性心律失常支持的最佳起搏器模式尚未确定。

方法

心室管理起搏与VVI 40起搏试验(MVP)是一项前瞻性、多中心、随机、单盲、平行对照临床试验,旨在确定在有ICD治疗标准适应证且无缓慢性心律失常起搏适应证的患者中,基于心房的双腔心室管理起搏模式(MVP)是否等同于或优于仅备用心室起搏(VVI 40)。MVP试验的设计效能为80%,以检测MVP治疗组中新发或恶化的心力衰竭或全因死亡率这一主要终点降低10%。在美国、加拿大、西欧和以色列的80个中心,约1000例患者在成功植入双腔ICD后将被随机分为MVP或VVI 40起搏组。将根据循证指南优化心力衰竭治疗。预先设定的次要终点将包括室性心律失常、心房颤动、缓慢性心律失常起搏的新适应证、健康相关生活质量和成本效益。入组于2004年10月开始,2006年4月结束。该研究将根据数据监测委员会的建议终止,或当最后一名入组并存活的患者达到至少2年随访时终止。

结论

MVP试验将满足临床需求,即开展精心设计的前瞻性研究,以明确在传统ICD患者中,基于心房的双腔最小心室起搏与单腔心室起搏相比的益处。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验